Key facts
- China's biopharmaceutical job market is recovering, with AI drug discovery roles up 84% and smart medical device positions up 113.1% in early 2026.
- Overseas expansion roles in the sector increased by 10.0%.
- Chinese biotech stocks have experienced a significant rebound, with the Hang Seng Biotech Index climbing over 80% this year.
- Government initiatives and policy frameworks are supporting domestic drug development and innovation.
- China's overall healthcare market is projected to reach $2.3 trillion by 2030.
China's biopharmaceutical job market is experiencing a rebound, driven by a surge in demand for roles in AI drug discovery, smart medical devices, and overseas expansion. Openings related to AI-driven drug discovery rose by 84.0% and those for smart medical devices increased by 113.1% in the first half of 2026 compared to the previous year, according to a report by Zhaopin.
This recovery coincides with a broader boom in China's biotech sector, with Chinese biotech stocks outperforming other emerging market growth trades. The Hang Seng Biotech Index has climbed over 80% this year, prompting many biotech firms to revive IPO plans in Hong Kong and Shanghai. This rally is supported by significant government investment and policy frameworks aimed at accelerating domestic innovation and global competitiveness in drug development.
The Chinese government, through initiatives like the 'Made in China 2025' strategy and the '14th Five-year Plan for the Development of the Pharmaceuticals Industry,' is prioritizing the biopharma sector. Regulatory reforms have streamlined approval processes and reduced development costs, making the market more attractive to investors. The country's large and aging population, coupled with a growing middle class, fuels domestic demand for advanced healthcare products and services, projecting the healthcare market to reach $2.3 trillion by 2030.